Barclays Maintains Overweight on Guardant Health, Raises Price Target to $150
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $120 to $150.
Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $120 to $150.